With Special Packaging, Sagent Gets FDA Approval For Heparin Products

0 comments

Posted on 6th July 2010 by gjohnson in Uncategorized

, , , , ,

In a much publicized case, actor Dennis Quaid’s newborn twins were accidentally given heparin overdoses in 2007. He blames the packaging of the drug for the mishap, with 10,000 unit and 10 unit heparin vials looking so similar that nurses confused them.  

Well, a heparin manufacturer has addressed that issue, and Tuesday asserted that its special labeling — with different  colors for each strength of heparin –  helped it to win Food and Drug Administration approval  for nine of its heparin products.
http://www.fiercepharmamanufacturing.com/story/packaging-contributes-approvals-sagents-heparin/2010-07-06

Sagent said it will launch its new heparin products, the heparin sodium injection USP,  immediately. In 2009 U.S. sales of heparin were about 306 million. 
http://www.pharmabiz.com/article/detnews.asp?articleid=56257&sectionid=

“Attaining FDA approval of Sagent’s heparin vials is a major accomplishment for our company,” CEO Jeffrey  Yordon said in a prepared statement. “Amidst the many challenges the nation’s supply of heparin has recently faced, Sagent identified and readied a reliable source for heparin and successfully navigated the FDA approval process for each of our heparin presentations. We believe that our innovative approach to the packaging and labelling of our heparin provides us with a significant advantage in the market by better meeting the requirements of patients and customers, positioning us for a successful launch.”

Sagent’s has proprietary PreventIV Measures packaging and labeling, which aids users in distinguishing between the nine presentations. Sagent’s packaging and labeling for heparin include using of a unique colour for each total strength; easy-to-read drug name, concentration and fill volumes; and cartons printed on all sides.

 PreventIV Measures is Sagent’s name for what it calls its user-driven and patient-centered approach to product labeling and packaging, which considers everyone handling medication along the way in order to help prevent medication errors.

“The pace of hospital care is faster than it has ever been, requiring increased vigilance to reduce treatment errors,”  Elaine Levy, system director for Pharmacy Sharp HealthCare in San Diego, California, said in a prepared statement.

 “Sagent’s PreventIV Measures approach to packaging and labeling design makes it easier to differentiate drugs from others in the same class, even when the medications look or sound alike,” she said. “Further, it makes it easier to distinguish between doses, which is especially important when working with medications like heparin that have a number of concentrations and sizes. I believe that features such as those incorporated into Sagent’s products can help reduce those errors caused by selecting the incorrect medication for a patient.”


PreventIV Measures is Sagent’s comprehensive, user-driven and patient-centred approach to product labelling and packaging that is designed to help prevent medication errors. It incorporates unique label and carton designs, cap and label colours, bar coding and other features that are designed to make it easier to differentiate drugs and identify the correct dose.


Attorney Gordon Johnson
Chair Traumatic Brain Injury Litigation Group, American Association of Justice
g@gordonjohnson.com :: 800-992-9447 :: Attorney Gordon S. Johnson, Jr.

http://subtlebraininjury.com :: http://brainanatomyguide.com :: http://car-accident-rain.com :: http://tbilaw.com
http://waiting.com :: http://vestibulardisorder.com :: http://youtube.com/profile?user=braininjuryattorney

FDA Criticized For Role In Heparin Contamination Case

0 comments

Posted on 30th April 2010 by gjohnson in Uncategorized

, , ,

A congressional probe has faulted the Food and Drug Administration for failing to identify the companies responsible for  contaminated heparin being imported from China to the United States, where it was linked to hundreds of deaths, according to a story in The Wall Street Journal Friday. http://online.wsj.com/article/SB10001424052748703572504575214420823549694.html?mod=WSJ_hpp_sections_news

That should come as no surprise to anyone with knowledge of that nightmarish heparin disaster. It’s rather obvious that the FDA was not doing its job, and still may not be doing its job in this regard, namely properly policing imported medicines and drugs.

Rep. Joe Barton, R-Texas, and Rep. Mike Burgess, R-Texas, in a letter to the FDA this week outlined the details of their investigation into the deadly heparin case. They told the agency that it had failed to follow up on several “specific and credible leads” that could have identified who was responsible for the contaminated blood thinner, The Journal reported.

Between 2007 and 2008 the contaminated imported heparin was tied to more than 80 deaths, and to hundreds of incidents where people fell sick.

Barton, the top Republican on the House Energy and Commerce Committee, has been spearheading the probe, and a vocal critic, of  how the FDA handled the tainted heparin situation.

The letter to the FDA asserted that the federal agency hasn’t done any follow-up with the Chinese government on issues related to some Chinese companies, according to The Journal.

The investigation also found that the FDA didn’t investigation leads it received from foreign officials. For example, one November 2008 FDA memo said that a respectable foreign government agency had shared “a significant finding” that a Chinese business was manufacturing counterfeit heparin with plans to ship it to the United States under another company’s name, The Journal reported.

China is the source of much of the world’s crude heparin, as that country processes pigs intestines as an ingredient for that drug.

Back in March 2008, the FDA announced that it had identified the heparin contaminant. It was chondroitin suflate, which was mixed into the raw heparin in China “to stretch the supply,” according to The Journal.

The FDA never announced who it thought was responsible for the contamination. But there seemed to be several obvious culprits.

The letter cited the case of  Chongqing Imperial Bio-Chem in China, which supplied pharmaceutical ingredients. An FDA document from April 2008 said that some of the crude heparin that Chongqing sent to an Ohio company was tainted, The Journal reported.

The FDA in March 2009 did ban pharmaceutical ingredients from Chongqing from coming to the states. But Barton and Burgress maintained that the agency should have probed further, in terms of Chonqging’s actual name and its place in the drug supply chain, according to The Journal.   

 The congressmen’s letter also pointed out that the FDA will have to overcome legal and language hurdles to conduct probes of drugs overseas


Attorney Gordon Johnson
Chair Traumatic Brain Injury Litigation Group, American Association of Justice
g@gordonjohnson.com :: 800-992-9447 :: Attorney Gordon S. Johnson, Jr.

http://subtlebraininjury.com :: http://brainanatomyguide.com :: http://car-accident-rain.com :: http://tbilaw.com
http://waiting.com :: http://vestibulardisorder.com :: http://youtube.com/profile?user=braininjuryattorney

Heparin Rival Is In A Pickle Over Patent For Angiomax

0 comments

Posted on 19th March 2010 by gjohnson in Uncategorized

, , ,

The manufacturer of a rival blood-thinner to the generic heparin is trying to overcome what The New York Times Friday called “one of the costliest blunders in drug industry history.” http://www.nytimes.com/2010/03/19/business/19patent.html

The Times story, headlined “A Company Races to Keep a Drug Patent,” describes the predicament of Parsippany, N.J.-based Medicines Co., which makes the blood thinner Angiomax.

In a clerical error that should have cost someone his or her job, Medicines back in 2001 missed a deadline to apply for a patient extension for Angiomax. So now that patent is set to expire next Tuesday, instead of in December 2014. That means generic versions of the drug will be able to come to market.

The drug maker has filed several appeals with patent officials over its goof, unsuccessfully. But Tuesday a federal judge ruled that the U.S. Patent and Trademark Office must reconsider its denial of Medicines’ 2001 filing.

The Times’ story outlines all of Medicines’ machinations to retain its patent on Angiomax. And that includes a convoluted argument by Medicines’ about its blood thinner versus heparin.

The drug makers has studies that maintain that it would save the health care system billions of dollars over the next two decades if Angiomax retains its patent.

Medicines argues that a continued patent would mean more promotion for Angiomax, and possibly new uses for it, according to The Times. So its use would increase at the expense of its main competitor, generic heparin.

Yet Angiomax is much pricier than heparin, at more than $600 a patient, versus pennies for heparin.

“But Medicines argues that Angiomax is actually cheaper for the health care system overall than heparin, partly because it causes less bleeding, a serious and costly side effect,” The Times writes.


Attorney Gordon Johnson
Chair Traumatic Brain Injury Litigation Group, American Association of Justice
g@gordonjohnson.com :: 800-992-9447 :: Attorney Gordon S. Johnson, Jr.

http://subtlebraininjury.com :: http://brainanatomyguide.com :: http://car-accident-rain.com :: http://tbilaw.com
http://waiting.com :: http://vestibulardisorder.com :: http://youtube.com/profile?user=braininjuryattorney

Baxter Having Issues Passing New Heparin-Potency Test

0 comments

Posted on 15th March 2010 by gjohnson in Uncategorized

, , , , ,

Baxter International, the maker of the blood thinner heparin, says it’s encountering problems having its drug pass a stricter drug-potency test, according to the magazine Modern Healthcare. http://www.modernhealthcare.com/article/20100315/NEWS/303159895

The update that has Baxter troubled has been devised by U.S. Pharmacopeia (USP), and provides potency reading for heparin that are 10 percent greater than the old test.

“It’s taking us a bit longer than anticipated to meet the requirements of the new test,” Baxter spokeswoman Kellie Hotz told Modern Healthcare.

She added that Baxter has been talking to the Food and Drug Administration about way it can meet the new USP standard.

The heparin that is currently being testing is pre-mixed product, not the concentrated vial product that was investigated by the FDA last year, Hotz told Modern Healthcare.


Attorney Gordon Johnson
Chair Traumatic Brain Injury Litigation Group, American Association of Justice
g@gordonjohnson.com :: 800-992-9447 :: Attorney Gordon S. Johnson, Jr.

http://subtlebraininjury.com :: http://brainanatomyguide.com :: http://car-accident-rain.com :: http://tbilaw.com
http://waiting.com :: http://vestibulardisorder.com :: http://youtube.com/profile?user=braininjuryattorney

FDA Soon To Issue Guides On Tracking/Tracing Drugs

0 comments

Posted on 13th March 2010 by gjohnson in Uncategorized

, , , ,

It may have taken three years since the heparin-contamination tragedy, but the Food and Drug Administration is apparently close to issuing its guidance for the tracking and tracing of medicines. http://www.securingpharma.com/40/articles/403.php

Joshua Sharfstein, FDA deputy commissioner, said Thursday that the guidance will set “a standard for unique identification for prescription drug packages, which ultimately will help in identifying the whereabouts and authenticity of drug packages and distinguish them from counterfeits.”

He made his remarks before a House Energy and Commerce health subcommittee meeting, which was called “Drug Safety: An Update From The FDA.”

Coming up with a better system of tracking drugs is crucial, especially when about 80 percent of all active pharmaceutical ingredients used by U.S. drug makers come from overseas, according to a 1998 U.S. General Accounting Office study.

During his testimony, Sharfstein claimed that the FDA has made great progress beefing up the oversight of foreign-made drug ingredients that are coming into the United States, For example, it has opened offices in several countries and now has information-sharing deals with foreign regulatory agencies.

Sharfstein also cited the calamity involving Chinese-made heparin, which he said caused the deaths at least 80 Americans, during his comments to the subcommittee.


Attorney Gordon Johnson
Chair Traumatic Brain Injury Litigation Group, American Association of Justice
g@gordonjohnson.com :: 800-992-9447 :: Attorney Gordon S. Johnson, Jr.

http://subtlebraininjury.com :: http://brainanatomyguide.com :: http://car-accident-rain.com :: http://tbilaw.com
http://waiting.com :: http://vestibulardisorder.com :: http://youtube.com/profile?user=braininjuryattorney

German Heparin Maker Sees 19 Percent Earnings Gains in 2009

0 comments

Posted on 26th February 2010 by gjohnson in Uncategorized

, , , ,

The German pharmaceutical giant Fresenius, which had a temporary monopoly for the blood thinner heparin when the drug was recalled in 2008, reported earnings growth of 19 percent for last year on Wednesday.

http://www.reuters.com/article/idUSLDE61L20X20100224?type=marketsNews


Fresenius’s financial results got a lift from its unit APP, which it acquired for $3.7 billion in 2008 as it sought to expand into the U.S. generic infusion drug market. APP’s competitors in that market are Hospira and Pfizer.

For a short period APP had a lock on the market for heparin, a dialysis drug, in the United States when Baxter International had to recall its heparin in 2008 because it was contaminated, causing many deaths.

But last August Hospira got regulatory approval for its heparin products, and it has taken much market share from APP, according to Reuters.


Attorney Gordon Johnson
Chair Traumatic Brain Injury Litigation Group, American Association of Justice
g@gordonjohnson.com :: 800-992-9447 :: Attorney Gordon S. Johnson, Jr.

http://subtlebraininjury.com :: http://brainanatomyguide.com :: http://car-accident-rain.com :: http://tbilaw.com
http://waiting.com :: http://vestibulardisorder.com :: http://youtube.com/profile?user=braininjuryattorney

Sen. Grassley Asks FDA For Update On Foreign Drug Inspection Improvements Since Heparin-Contamination Deaths

0 comments

Posted on 17th February 2010 by gjohnson in Uncategorized

, , , , , ,

At least one lawmaker hasn’t forgotten the 2008 heparin-contamination tragedy, which resulted in untold numbers of people dying. Sen. Chuck Grassley (R-Iowa) has renewed his quest to hold the U.S. Food and Drug Administration accountable for improving foreign drug inspections so deadly incidents like the blood-thinner debacle doesn’t happen again.

Earlier this week Grassley, who since 2007 has twice filed legislation seeking to “beef up” the FDA’s foreign inspection operation, sent a letter to the federal agency seeking a progress report on improvements to inspections.

Here is the senator’s press release on the matter, and the full text of his letter.
http://www.iowapolitics.com/index.iml?Article=185684

In seeking a follow-up, Grassley is essentially trying to hold the FDA’s feet to the fire for commitments it made when Baxter International temporarily suspended production of its blood thinner heparin in 2008 because of adverse reactions.

“My letter today follows up on oversight I did at that time because requirements the FDA already had in place then were not met by the FDA, and the drug company itself didn’t have a system to check the quality of upstream providers of the drug components,” Grassley said in statement. “In fact, pharmaceutical companies aren’t required to have those checks in place.”

That is terrifying information for anyone who takes medication in this country.

“I will continue asking the FDA for information and working to hold the federal agency accountable in its work to protect the safety of the drugs in our medicine cabinets,” Grassley said.

His proposed legislation calls for the enhanced enforcement for quality and safety violations. But the bills, which Grassley had introduced with the late Sen. Ted Kennedy (D-Mass), hasn’t been passed by Congress.

As many of our readers will know, Grassley is one of the chief Republican obstacles to the passage of health care reform. The irony of that contrasted against his outrage with Heparin is a bit much.

Grassley’s press release noted that China is one of the largest exporters of pharmaceutical products to the United States. Following questions raised by him others in 2007 and 2008 about the inadequate foreign inspections, the FDA has opened an office in China to facilitate inspections.

Dow Jones wrote a story on Grassley’s call for answers and an update from the FDA.
http://www.nasdaq.com/aspx/stock-market-news-story.aspx?storyid=201002161801dowjonesdjonline000426&title;=sengrassley-asks-fda-about-monitoring-of-drugs-made-abroad

That article says that 80 deaths were blamed on contaminated heparin, a blood thinner, from China. Based on the number of wrongful death claims that have been filed against Baxter, that number may be seriously understated. The contaminant, oversulfated chondroitin sulfate, OSCS, was in the heparin that Baxter received from is supplier Chanzghou SPL. Chanzghou SPL is a subsidiary of a Wisconsin company, SPL.

Grassley wants the FDA to answer his letter by March 2.

Don’t expect too much. While Grassley’s position is laudable, more should be done by Congress to get a full accounting of just how many people Baxter and SPL killed.

Congress should be publicly asking these questions of all of the heparin players, not just the FDA:
  • How many wrongful death claims has Baxter received?
  • How many doses of the contaminated heparin were actually given to people?
  • Why didn’t Baxter react more quickly when it learned of the deaths?
  • Why didn’t Baxter have some type of tracking system on its products so that when it learned of the contamination, it could quickly pull all of the tainted product from its shelf?
  • Why wasn’t the FDA and Baxter more concerned about the risk of counterfeiting drugs?


Attorney Gordon Johnson
Chair Traumatic Brain Injury Litigation Group, American Association of Justice
g@gordonjohnson.com :: 800-992-9447 :: Attorney Gordon S. Johnson, Jr.

http://subtlebraininjury.com :: http://brainanatomyguide.com :: http://car-accident-rain.com :: http://tbilaw.com
http://waiting.com :: http://vestibulardisorder.com :: http://youtube.com/profile?user=braininjuryattorney

Traceability And The Recalls of Deadly Heparin and Peanuts

0 comments

Posted on 11th February 2010 by gjohnson in Uncategorized

, , , , ,

Traceability, the ability of a manufacturer to track where it secured raw materials and where it shipped product, is a key issue in lawsuits regarding heparin, the tainted blood thinner that was recalled and is being blamed for causing countless U.S. deaths in 2007 and 2008. http://heparin-law.com

InTech Home, from the International Society of Automation, has a detailed analysis of the issue of traceability and suggests requirements for traceability systems. http://www.isa.org/InTechTemplate.cfm?Section=General_Information2&template;=/ContentManagement/ContentDisplay.cfm&ContentID;=81071

The article cites a number of pharmaceutical and food product recalls where traceability has been an issue, including heparin that came from China and had a deadly contaminant in it, allegedly killing people. The story also mentions two salmonella outbreaks: One caused by jalapeno peppers from Mexico, which sickened 1,442 people, in 2008; and the eight deaths, and sickening of more than 600 people, from foods containing tainted peanuts that same year.

“While the current U.S. Bioterrorism Act requires traceability known as ‘one up and one down,’ recent food scares such as contaminated peanuts and peppers have demonstrated true recalls and safety announcements multiple supplier cooperation,” the story says.

The article says traceability has to do with determining what lots went into a product, and that such “lot assignments are the norm in drug manufacturing.” Lawyers have a lot of questions for heparin makers about traceability and lots during litigation stemming from the deaths two years ago.

As for traceability standards, the story makes six suggestions for food products.

The story’s first recommendation for the food industry is to first create a system that identifies “all source component ingredients” of a product within seconds. The second is to enable tracing of any ingredient “to identify all associated products within seconds,” Third is to quickly implement the recommended practices. Fourth is to address public concerns about tracing products. Fifth is to create a low-cost, low-burden traceability system. Sixth is to support other industry safety initiatives.

Finally, the article calls for standard lot identification of food products, suggesting “a new universal 16-character code as a consistent method of identification.”


Attorney Gordon Johnson
Chair Traumatic Brain Injury Litigation Group, American Association of Justice
g@gordonjohnson.com :: 800-992-9447 :: Attorney Gordon S. Johnson, Jr.

http://subtlebraininjury.com :: http://brainanatomyguide.com :: http://car-accident-rain.com :: http://tbilaw.com
http://waiting.com :: http://vestibulardisorder.com :: http://youtube.com/profile?user=braininjuryattorney

Baxter Heparin Debacle from a Financial Perspective

0 comments

Posted on 24th December 2009 by gjohnson in Uncategorized

, , , , ,

Criticism of the greed based decision making of exporting the manufacture of Heparin to China came from an interesting direction yesterday. The source: Norm Howe, Senior Partner at Validation and Compliance Institute, consultants for FDA regulated industries. Mr. Howe had this to say:

When FDA inspected a Heparin supplier, Shanghai No. 1 Biochemical & Pharmaceutical Co. Ltd., they thought they were seeing the real plant. It turned out that it was only a show facility. The real plant was a shadow plant located somewhere else. The US-FDA Warning Letter later stated, “The inspection revealed that the facility was not manufacturing, and did not appear to have ever manufactured, Heparin Sodium USP (or heparin sodium) for the U.S. market.”

This case is similar to Baxter Pharmaceutical’s experience with their Heparin supplier in 2008. The result of that deception was that hundreds of patients suffered life-threatening reactions like severe hypotension, low blood pressure and over 80 people died.
See A New Paradigm to Address the High Cost of Vendor Qualification
http://www.costa-classified-ads.com/manag/3515/a-new-paradigm-to-address-the-high-cost-of-vendor-qualification/ In this article, Mr. Howe went on to point out that saving a few dollars on Chinese imports, may end up costing your company exponentially more.

He continued:

Any pharmaceutical or medical device plant is a very complex place. Unless you plan to take up residence at the vendor you have no chance to understand the true nature of these operations. And what company in today’s cost-cutting climate has the resources to do that? Keep in mind that an audit costs more than what you pay for your auditors to investigate the vendor. The vendor has to spend their time escorting the auditors around, digging out records, and following up on action items. Guess who has to cover that cost. The assumption today is that a BETTER audit means a LONGER audit. There has to be another way.

What’s needed is a new paradigm for vendor qualification; a tool that can drill deeply into the vendor’s operation at low cost; something that can provide a more lasting measure of the vendor’s performance than simply an audit.


Isn’t there a simpler solution? Manufacture drugs in the United States where the company whose name is on the product, can control what goes in them?


Attorney Gordon Johnson
Chair Traumatic Brain Injury Litigation Group, American Association of Justice
g@gordonjohnson.com :: 800-992-9447 :: Attorney Gordon S. Johnson, Jr.

http://subtlebraininjury.com :: http://brainanatomyguide.com :: http://car-accident-rain.com :: http://tbilaw.com
http://waiting.com :: http://vestibulardisorder.com :: http://youtube.com/profile?user=braininjuryattorney

America Exporting our Well Being to China – From Heparin to Green Tech

0 comments

Posted on 6th October 2009 by gjohnson in Uncategorized

, , , , ,

China exports what American’s want. Not because they do it better, but because they do it cheaper. Baxter’s Heparin debacle is the perfect example. Anyone who lives in the Midwest knows that we grow all the corn necessary to domestically raise all the pigs we need. The raw material for Heparin comes from the small intestines of pigs.

Yet Baxter and its supplier SPL went off to China to get Heparin. The reason of course was to save pennies on each dose. Somehow, someone at Baxter decided that maintaining manufacturing and quality control over this most dangerous of products wasn’t as important as those pennies per dose.

The problem for American society is that China, despite its communist political system, always seems to be motivated by the “green” in greed equation. The irony of that now is that even though China is seen as the world’s worst polluter, they appear to be poised to receive the green, for Going Green.

On Point, the NPR program/podcast did an excellent piece on China’s Going Green, “Green China & the Clean-Tech Race”. To get the Podcast from September 30th go to http://www.onpointradio.org/2009/09/green-china-and-the-clean-tech-race

The program listing begins with this teaser:

“On Capitol Hill today, the Senate introduces a bill meant to slow global warming. Meanwhile, back on the wind farm, American entrepreneurs are taking the problem seriously — as an environmental threat but also as the next great economic prize.
“In China, the government says it’s determined to become a green superpower — or risk drowning in its own pollution.
“Some say the next great global race is on — the clean-tech race — and that China’s entry is a “Sputnik moment.”
“Has America heard the wake-up call? Is there a clean-energy race to be won or lost? This hour, On Point: China, the U.S., and the clean-energy future.”
One of the guests in this podcast is Michael Splinter, whose American based firm, Applied Materials, is about to open the world’s largest privately funded solar research facility — in Xian, China. For more on Splinter and his company go to http://www.appliedmaterials.com/about/bio_michael_splinter.html

The Heparin Catastrophe is not just a crisis about the safety of American pharmaceuticals. It is also a crisis about American jobs, technology and economic growth. If the greed equation results in the U.S. corporations exporting the manufacturer and development of this next tech explosion to China, our prosperity made be forever compromised.


Attorney Gordon Johnson
Chair Traumatic Brain Injury Litigation Group, American Association of Justice
g@gordonjohnson.com :: 800-992-9447 :: Attorney Gordon S. Johnson, Jr.

http://subtlebraininjury.com :: http://brainanatomyguide.com :: http://car-accident-rain.com :: http://tbilaw.com
http://waiting.com :: http://vestibulardisorder.com :: http://youtube.com/profile?user=braininjuryattorney